Commercialisation activities promote and support the research enterprise at the Australian Stem Cell Centre (ASCC) by creating relationships with the private sector to develop, protect, transfer and commercialise research results in line with the Centre’s Objectives.
Commercialisation activity involves the movement of research results from the laboratory toward the marketplace.
The ASCC jointly owns the IP developed under its research streams with the research institutes carrying out the research. In order to help accomplish the commercialisation of this research, the ASCC in partnership with the research institutes facilitates the protection and further development of technologies developed by the research teams working under the ASCC’s Collaborative Streams.
The ASCC has a variety of mechanisms at its disposal to help achieve its commercialisation goals, including the evaluation, patenting, and licensing of novel technologies and methods invented through ASCC funded research.
The ASCC is involved in negotiating Material Transfer Agreements (MTA) and other legal documents that enable the sharing of materials and resources between the ASCC funded scientists and the academic and private sectors. This sharing may range from obtaining single, critical reagents to setting up formal research collaborations.
The ASCC can also facilitate and broker contractual arrangements between ASCC researchers, their host institutions and the private sector. As part of this capacity, it also provides ASCC funded researchers with general advice on intellectual property, conflict-of-interest issues, and related matters.
Technologies available for license:
APEL Culture Medium
APEL (Albumin Polyvinylalcohol Essential Lipids) medium is a chemically defined serum free cell culture medium that provides a robust platform for the differentiation of human Embryonic Stem cells (HESCs). Unlike alternative culture mediums, APEL does not contain serum or serum derived components that are undefined and subject to lot-to-lot variability, which can influence the outcome of differentiation experiments and modify the effects of added growth factors. APEL has been used in combination with multiple combinations of growth factor cocktails to differentiate HESCs into cells of all 3 germ layers as determined by marker expression. Download license proposal.
Mel-3 Licensing Proposal
MEL-3 is a HESC line that was derived upon a human feeder cell line in serum free cell culture medium. This cell line exhibits typical HESC morphology and has been demonstrated to express a number of cell surface and intracellular markers of undifferentiated HESCs. Additionally, independent histology analysis confirms teratoma formation. Download license proposal.
Mel-4 Licensing Proposal
MEL-4 is a HESC line that was derived upon a human feeder cell line in serum free cell culture medium. This cell line exhibits typical HESC morphology and has been demonstrated to express a number of cell surface and intracellular markers of undifferentiated HESCs. Additionally, independent histology analysis confirms teratoma formation. Download license proposal.
SPIN HES Cell Differentiation System
The SPIN Human Embryonic Stem (HES) Cell Differentiation System is an advantageous method for the differentiation of human ES cells. Unlike alternative differentiation techniques, SPIN results in the reproducible formation of Embryoid Bodies (EBs) of uniform cell size. When used in conjunction with APEL medium (see alternate ASCC proposal), the SPIN system provides a unique, robust method for growth directed human ES cell differentiation. Download license proposal.